Literature DB >> 7197541

[Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration].

H M Kellner, C Arnold, O E Christ, H G Eckert, J Herok, I Hornke, W Rupp.   

Abstract

1. Following the dermal application of the carbon-14 labelled broad spectrum antimycotic 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Hoe 296, Batrafen) in the form of a 1% aqueous cream to healthy human dorsal skin (penetration time: 6 h; occlusive dressing for 5 h), percutaneous absorption accounted on average for 1.3% of the dose applied. Excretion occurred via the kidney, with biological half-lives of 1.7 h. As can be seen from penetration studies of cadaverous skin, the horny layer contained the highest concentrations, with values of 2300-4500 microgram/cm3. The levels determined in the corium were still above the minimum inhibitory concentrations. These concentrations were already obtained at the first test stage (1.5 h after application) and did not change virtually at all over the longer penetration period. According to studies using histoautoradiography, ciclopirox can penetrate the skin via the epidermis and the hair follicles. When ciclopirox-14C-olamine aqueous cream was spread on the surface of fingernails, the radioactive-labelled compound penetrated right through the nail. The percutaneous absorption in dogs was higher, at 5-15% of the dose, than it was in humans. 2. After vaginal application (1 mg/kg) of ciclopirox-14C-olamine in the form of a 1% aqueous cream to bitches, between 42 and 97% of the dose (depending on the animal) was recovered in the urine and faeces, the remainder having penetrated into the tampon used to close the vagina. 3. Ciclopirox is excreted by dogs and man in the urine, primarily as a glucuronide. In humans another glucuronide with properties similar to those of the original substance was detected. Two conjugated, relatively non-polar metabolites were also present in small amounts. The metabolite patterns after oral and dermal application were similar. The binding of ciclopirox to serum proteins in humans was 96 +/- 2% in a concentration range of 0.01-11.0 microgram/ml. 4. Placental transfer was low in the rats studied. Though there was good absorption by the mother animal, the radioactivity in the foetal tissues was always lower than that of the maternal blood.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7197541

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  13 in total

Review 1.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

2.  Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs.

Authors:  Scott J Weir; Robyn Wood; Karl Schorno; Amanda E Brinker; Prabhu Ramamoorthy; Kathy Heppert; Lian Rajewski; Mehmet Tanol; Tammy Ham; Michael J McKenna; William McCulloch; Michael Dalton; Gregory A Reed; Roy A Jensen; Michael J Baltezor; Shrikant Anant; John A Taylor
Journal:  J Pharmacol Exp Ther       Date:  2019-05-21       Impact factor: 4.030

Review 3.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 4.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.

Authors:  Alessandro Subissi; Daniela Monti; Giuseppe Togni; Federico Mailland
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

Review 5.  Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.

Authors:  S G Jue; G W Dawson; R N Brogden
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

Review 6.  Reposition of the Fungicide Ciclopirox for Cancer Treatment.

Authors:  Zhu Huang; Shile Huang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2021       Impact factor: 3.038

7.  Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A.

Authors:  Tao Shen; Chaowei Shang; Hongyu Zhou; Yan Luo; Mansoureh Barzegar; Yoshinobu Odaka; Yang Wu; Shile Huang
Journal:  Genes Cancer       Date:  2017-03

8.  Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.

Authors:  Chrysovalantou Mihailidou; Pavlos Papakotoulas; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  Oncotarget       Date:  2017-12-08

9.  CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer.

Authors:  Jing Zhou; Lu Zhang; Meng Wang; Li Zhou; Xuping Feng; Linli Yu; Jiang Lan; Wei Gao; Chundong Zhang; Youquan Bu; Canhua Huang; Haiyuan Zhang; Yunlong Lei
Journal:  Theranostics       Date:  2019-07-28       Impact factor: 11.556

10.  Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation.

Authors:  Tao Shen; Hongyu Zhou; Chaowei Shang; Yan Luo; Yang Wu; Shile Huang
Journal:  Genes Cancer       Date:  2018-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.